Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3904 results
NovoBiotic reports discovery of new antibiotic teixobactin
By PBR Staff Writer
NovoBiotic Pharmaceuticals has announced the discovery and preclinical development of a new antibiotic compound, teixobactin.
Drug Research > Drug Discovery & Development > News
Mirati begins dosing in Phase II trial of mocetinostat to treat bladder cancer
By PBR Staff Writer
Mirati Therapeutics has dosed the first patient in a Phase II clinical trial of mocetinostat, an orally-bioavailable, spectrum-selective HDAC inhibitor, as treatment for a select group of patients with bladder cancer.
Drug Research > Drug Discovery & Development > News
MMRF, GNS Healthcare collaborate to identify potential new multiple myeloma therapies
GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, and the Multiple Myeloma Research Foundation (MMRF), a leader in accelerating the development of breakthrough multiple myeloma therapies, announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma.
Drug Research > Drug Discovery & Development > News
Fennec completes patient enrollment in sodium thiosulfate phase III SIOPEL 6 study
Fennec Pharmaceuticals reported the second sodium thiosulfate Phase III study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is now closed for recruitment.
Drug Research > Drug Discovery & Development > News
Tekmira provides update on TKM-PLK1 Phase I/II clinical trial
Tekmira Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
Drug Research > Drug Discovery & Development > News
NephroGenex announces positive results for QT study of Pyridorin
NephroGenex, a pharmaceutical company focused on the development of therapeutics to treat kidney disease, has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin.
Drug Research > Drug Discovery & Development > News
Tekmira signs TKM-Ebola-Guinea clinical trial agreement with Oxford University
By PBR Staff Writer
Canadian RNAi therapeutics developer Tekmira Pharmaceuticals (TKM) has entered into a manufacturing and clinical trial agreement with the University of Oxford to test the new TKM-Ebola-Guinea drug in humans.
Drug Research > Drug Discovery & Development > News
BioCryst begins OPuS-2 clinical trial of BCX4161 to treat patients with Hereditary Angioedema
BioCryst Pharmaceuticals has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE).
Drug Research > Drug Discovery & Development > News
iCardiac Technologies IQ-CSRC study shows potential for faster drug development
The Food and Drug Administration hosted the Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier in clinical development.
Drug Research > Drug Discovery & Development > News
BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates
By PBR Staff Writer
Clinical-stage biopharmaceutical company BioLineRx and Novartis Pharma have reached a multi-year strategic collaboration agreement to support the development and commercialization of Israeli-sourced drug candidates.
Drug Research > Drug Discovery & Development > News
Novogen announces breakthrough discovery melanoma treatment
Novogen, Australian/US biotechnology company, announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.
Drug Research > Drug Discovery & Development > News
ChemoCentryx reports positive results from Phase II diabetic nephropathy trial of CCX140
ChemoCentryx, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2.
Drug Research > Drug Discovery & Development > News
Lakewood-Amedex seeks FDA approval for Phase I/IIa trial of Nu-3 for diabetic foot infections
By PBR Staff Writer
US-based biopharmaceutical firm Lakewood-Amedex has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct a Phase I/IIa trial of Nu-3 as a topical antimicrobial treatment for diabetic foot infections.
Drug Research > Drug Discovery & Development > News
Sunovion reports positive results from first placebo-controlled trial of dasotraline in ADHD patients
Sunovion Pharmaceuticals (Sunovion) announced positive results from the first placebo-controlled clinical study of the company’s investigational drug dasotraline for the treatment of adult patients with attention deficit hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
Janssen, USAID to expand access to anti-multidrug-resistant tuberculosis compound
By PBR Staff Writer
Johnson & Johnson's affiliate Janssen Therapeutics has signed a Memorandum of Understanding (MOU) with the US Agency for International Development (USAID) to fight against the antibiotic-resistant bacteria threat.
Drug Research > Drug Discovery & Development > News
61-75 of 3904 results